Omeprazol Farma Tarbis (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Farma Tarbis, is a Proton Pump Inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omeprazol Farma Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Farma Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal erosion. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑induced ulcer prophylaxis: lowers the risk of ulcer development in patients requiring long‑term NSAID therapy.

Adverse reactions to omeprazole are generally mild to moderate and vary with duration of therapy.

Common Side Effects: - Headache: mild, transient headache reported by some patients. - Diarrhea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis associated with prolonged use. - Hypomagnesemia: low serum magnesium levels with long‑term therapy. - Vitamin B12 deficiency: impaired absorption with extended treatment. - Acute interstitial nephritis: kidney inflammation reported rarely. - Stevens‑Johnson syndrome: severe skin reaction, extremely rare. - Hepatic injury: abnormal liver function tests in rare cases.

When prescribing omeprazole, clinicians should consider several safety aspects.

- Assess need for long‑term therapy: evaluate risk‑benefit before chronic use. - Monitor electrolytes: check magnesium and calcium levels during extended treatment. - Review concomitant medications: consider potential drug‑drug interactions. - Use with caution in hepatic impairment: dose adjustment may be required. - Pregnancy and lactation: weigh benefits against potential risks. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, loss of antiviral efficacy. - Dasatinib: lowered plasma concentrations, reduced therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Phenytoin: altered serum levels, adjust dose as needed. - Methotrexate: increased exposure, especially at high doses. - Digoxin: modest rise in serum concentration, observe for toxicity.